The WAVE trial was designed to evaluate the efficacy ... The proportion of AVG patients who were free from an adverse event was higher than the safety PG (95.4% vs. 89.0%, p=0.0162).

The WAVE trial was designed to evaluate the efficacy ... The proportion of AVG patients who were free from an adverse event was higher than the safety PG. Don't Miss our Black Friday Offers ...

The proportion of AVG patients who were free from an adverse event was higher than the safety PG (95.4% vs. 89.0%, p=0.0162). “In light of the historically low patency rates for AVG patients, the ...